These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27411698)

  • 1. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control.
    Famulla S; Hövelmann U; Fischer A; Coester HV; Hermanski L; Kaltheuner M; Kaltheuner L; Heinemann L; Heise T; Hirsch L
    Diabetes Care; 2016 Sep; 39(9):1486-92. PubMed ID: 27411698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
    McVey E; Hirsch L; Sutter DE; Kapitza C; Dellweg S; Clair J; Rebrin K; Judge K; Pettis RJ
    J Diabetes Sci Technol; 2012 Jul; 6(4):743-54. PubMed ID: 22920798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closed-Loop Control of Postprandial Glycemia Using an Insulin-on-Board Limitation Through Continuous Action on Glucose Target.
    Rossetti P; Quirós C; Moscardó V; Comas A; Giménez M; Ampudia-Blasco FJ; León F; Montaser E; Conget I; Bondia J; Vehí J
    Diabetes Technol Ther; 2017 Jun; 19(6):355-362. PubMed ID: 28459603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
    Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
    Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.
    Nosek L; Cardot JM; Owens DR; Ibarra P; Bagate K; Vergnault G; Kaiser K; Fischer A; Heise T
    Diabetes Obes Metab; 2012 Dec; 14(12):1137-44. PubMed ID: 22988932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients.
    Schernthaner G; Wein W; Sandholzer K; Equiluz-Bruck S; Bates PC; Birkett MA
    Diabetes Care; 1998 Apr; 21(4):570-3. PubMed ID: 9571344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.
    Dassau E; Renard E; Place J; Farret A; Pelletier MJ; Lee J; Huyett LM; Chakrabarty A; Doyle FJ; Zisser HC
    Diabetes Obes Metab; 2017 Dec; 19(12):1698-1705. PubMed ID: 28474383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM.
    Burge MR; Castillo KR; Schade DS
    Diabetes Care; 1997 Feb; 20(2):152-5. PubMed ID: 9118763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
    Kipnes M; Dandona P; Tripathy D; Still JG; Kosutic G
    Diabetes Care; 2003 Feb; 26(2):421-6. PubMed ID: 12547873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
    Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
    Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.
    Galic E; Vrtovec M; Bozikov V; Schwarzenhofer M; Milicevic Z
    Med Sci Monit; 2005 Dec; 11(12):PI87-92. PubMed ID: 16319804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.